Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 11Gynecologic 3Gastrointestinal 3Thoracic 2Dermatologic 2Lymphoid 1Head & Neck 1Breast 1

Conditions

Melanoma 15Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Carcinoma, Merkel Cell 5Breast Neoplasms 5Small Cell Lung Carcinoma 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Neoplasm Metastasis 3Lymphoma, T-Cell, Cutaneous 3Carcinoma, Hepatocellular 3Stomach Neoplasms 2Sarcoma 2Lung Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Uveal Melanoma 1Turcot syndrome 1Thyroid Neoplasms 1Testicular Neoplasms 1Skin Neoplasms 1Sezary Syndrome 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 27Nivolumab 20atezolizumab 6Ipilimumab 6Magnetic Resonance Spectroscopy 5Specimen Handling 4Paclitaxel 4Docetaxel 4Cyclophosphamide 4Carboplatin 4fludarabine 3avelumab 3Pemetrexed 3Interleukin-2 3tislelizumab 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Radiosurgery 2Cisplatin 2veliparib 1toripalimab 1spartalizumab 1sotigalimab 1sonidegib 1sargramostim 1regorafenib 1poly ICLC 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × durvalumab × Dermatologic × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡